TD Cowen initiated coverage of Benitec Biopharma (BNTC) with a Buy rating and no price target The company’s DNA-directed ‘silence and replace’ platform combines RNAi silencing sequences with replacement genes, the analyst tells investors in a research note. The firm believes Benitec’s lead asset BB-301 for oculopharyngeal muscular dystrophy showed “compelling” Phase 1/2 clinical data, with improving subjective and objective dysphagia measures in three patients.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTC:
- Innovative Gene Therapy Approach Drives Buy Rating for Benitec Biopharma
- Benitec Biopharma files to sell 900K shares of common stock for holders
- Positive Buy Recommendation for Benitec Biopharma Driven by Promising Clinical Progress and Strong Financial Position
- Benitec Biopharma reports Q3 EPS (24c) vs. (23c) last year